Is BIIB a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,676 people get BIIB articles and Market Currents by email alert.

Get email alerts on BIIB »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Bull Of The Day: Biogen
Zacks Investment Research • Fri, Jun 14
Cowen Questions Sales Growth Of Biogen Idec's MS Drug Tecfidera
Brian L. Wilson • Thu, Jun 6 • 2 Comments
Biogen Idec - Too High Too Fast?
William Meyers • Tue, Apr 30 • 5 Comments
Tecfidera Raises The Bar For Biogen Idec
Brian L. Wilson • Mon, Apr 1
Biogen Gets FDA Approval For MS Treatment Tecfidera
Profit Fan • Thu, Mar 28
Biogen And The Progress In Multiple Sclerosis Treatment
Peter Geschek • Mon, Mar 25 • 4 Comments
Several Catalysts Behind My Decision To Establish A Position In Biogen Idec
Heather Ingrassia • Tue, Mar 5
Has Biogen Moved Too Far Too Fast?
Valuentum • Wed, Feb 27 • 1 Comment
Biogen Idec: Solid Execution Trumps A Thinning Pipeline
PropThink • Fri, Feb 8
Biogen Idec Pays Elan $3.25 Billion For Tysabri: Do We Leave, Or Stay?
Prohost Biotech • Wed, Feb 6 • 2 Comments
Biogen Idec: The Strong Performance Speaks For Itself
Felix Pinhasov • Wed, Jan 30
Biogen Idec Has BG-12, But What Excites Investors Next?
Stephen Simpson • Tue, Jan 29 • 2 Comments
Biogen Idec Retools After ALS Drug Trial Failure
Alan Kotok • Sun, Jan 6 • 12 Comments
Biogen Idec: Buy A Winner
QuandaryFX • Wed, Nov 7, 2012 • 1 Comment
Biogen Idec And The Race To Cure Multiple Sclerosis
Peter Geschek • Fri, Oct 12, 2012 • 1 Comment
Is Biogen Too Good To Be True?
Amit Bilgi • Tue, Sep 18, 2012 • 1 Comment
Biogen Idec Gearing Up For Major Launches
Stephen Simpson • Tue, Apr 10, 2012 • 2 Comments
Biogen Idec Turns A Mess Into A Double Win
Jessica King Holden • Sun, Jan 22, 2012 • 2 Comments
Biogen's Big Multiple Sclerosis Bet Is About To Be Rewarded ... Again
Todd Campbell • Tue, Jan 17, 2012 • 3 Comments
Biogen: A 'Decimated' Pipeline?
Derek Lowe • Tue, Jan 17, 2012

Biogen Idec Has BG-12, But What Excites Investors Next?
Stephen Simpson • Tue, Jan 29 • 2 Comments

Elan Is In Play
Robert Wu • Sat, Jun 15 • 9 Comments
The Biggest Companies That Don't Pay Dividends - But May Be About To
StreetAuthority • Fri, Jun 14
Novartis: 5-Year Revenue Outlook
Bio Vantage • Thu, Jun 13 • 6 Comments
The Key To Creating Large Gains: Patience
Brian Nichols • Tue, Jun 4 • 9 Comments
Cramer's Mad Money - The Miraculous Six Flags (5/22/13)
SA Editor Miriam Metzinger • Thu, May 23
S&P 500 Growth Stocks Portfolio That Can Outperform The Market By A Big Margin
Arie Goren • Mon, May 20
This Big Hedge Fund Is Bullish On Big Companies; Should You Be?
Insider Monkey • Mon, May 13 • 1 Comment
Cramer's Lightning Round - Selling SunTrust Was A Mistake (5/9/13)
SA Editor Miriam Metzinger • Fri, May 10 • 1 Comment
3 Bio Companies Facing The Patent Cliff
Emerging Equities • Tue, May 7 • 1 Comment
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Biotechnology: Strong Fundamentals Are The Basis Of Strong Performance
Ryan's View • Fri, May 3 • 5 Comments
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments
Best And Worst Performing S&P 500 Stocks On Earnings
Bespoke Investment Group • Fri, Apr 26 • 1 Comment
Cramer's Mad Money - Why Analysts Were Wrong About Microsoft (4/25/13)
SA Editor Miriam Metzinger • Fri, Apr 26 • 11 Comments
Cramer's Mad Money - National Lemming Day (4/24/13)
SA Editor Miriam Metzinger • Thu, Apr 25
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Tue, Apr 23 • 1 Comment
Biotech Stocks Get A Turbo Boost From Vertex
Rod Raynovich • Sat, Apr 20 • 3 Comments
AVEO Poised To Move Higher Before FDA Adcomm Catalyst, Obamacare And Platform Potential
Scott Matusow • Tue, Apr 16 • 43 Comments
S&P 500's P/E Rises To 16.4x As Q1 Results Start Coming In
Pendulum • Sun, Apr 14 • 4 Comments
Acorda: A Biotech Company To Consider
Northrop Puckett • Sat, Apr 13 • 1 Comment

Biogen Idec Inc. - Shareholder/Analyst Call
Wed, Jun 12
Biogen Idec Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, Apr 25
Biogen Idec's Management Presents at Citi 2013 Global Healthcare Conference (Transcript)
Mon, Feb 25
Biogen Idec Management Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Jan 28
Biogen Idec Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012
Biogen Idec Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Jul 24, 2012
Biogen Idec's CEO Hosts 2012 Analyst Day (Transcript)
Tue, Jun 12, 2012 • 1 Comment
Biogen Idec's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, May 1, 2012
Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Jan 31, 2012
Biogen Idec's CEOPresents at The 30th Annual JPMorgan Chase Healthcare Conference (Transcript)
Tue, Jan 10, 2012
Biogen Idec's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011
Biogen Idec Inc. - Special Call
Wed, Oct 26, 2011
Biogen Idec's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Jul 26, 2011
Biogen Idec's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Thu, Apr 21, 2011
Biogen Idec's CEO Discusses Q4 2010 Results - Earnings Call Transcript
Tue, Feb 1, 2011
Biogen Idec CEO Discusses Q3 2010 Results - Earnings Call Transcript
Tue, Oct 26, 2010
Biogen Idec Inc. Q2 2010 Earnings Call Transcript
Tue, Jul 20, 2010
Biogen Idec, Inc. Q1 2010 Earnings Call Transcript
Tue, Apr 20, 2010
Biogen Idec, Inc. Q4 2009 Earnings Call Transcript
Tue, Feb 9, 2010 • 1 Comment
Biogen Idec Inc. Q3 2009 Earnings Call Transcript
Tue, Oct 20, 2009

Movers & Shakers: Wednesday’s movers: H-P up as CEO touts turnaround

at MarketWatch.com (Jun 12, 2013)
Biogen Idec 2013 Annual Shareholder Meeting Webcast

Business Wire (Jun 4, 2013)
Cramer: Out with the New, In with the Old

at CNBC.com (Jun 3, 2013)
Jeff Reeves's Strength in Numbers: 3 ways to play the biotech boom

at MarketWatch.com (Jun 3, 2013)
Biogen Idec Reinforces Commitment to MS Community on 5th Annual World MS Day

Business Wire (May 29, 2013)
Biogen Idec to Present at the Jefferies 2013 Global Healthcare Conference

Business Wire (May 28, 2013)
Biogen Idec Appoints Spyros Artavanis-Tsakonas Chief Scientific Officer

Business Wire (May 23, 2013)
Biogen Idec to Present at the Deutsche Bank 38th Annual dbAccess Healthcare Conference

Business Wire (May 22, 2013)
Biogen Idec Submits Application to FDA for Approval of PLEGRIDY™ (Peginterferon Beta-1a) in Multiple Sclerosis

Business Wire (May 21, 2013)
Jim Cramer's 5 Investing Sweet Spots

at CNBC.com (May 14, 2013)
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor VIII Therapy for Hemophilia A

Business Wire (May 13, 2013)
Lightning Round: SunTrust, Nokia & More

at CNBC.com (May 9, 2013)
Michael Sincere's Long-Term Trader: Why I stopped using stop loss orders

at MarketWatch.com (May 9, 2013)
Midday Movers: MSFT, IBM, AAPL & More

at CNBC.com (Apr 29, 2013)
Top Undervalued Pharma Stock: Analyst

at CNBC.com (Apr 29, 2013)
Biotech’s latest rally: exuberance or execution?

at MarketWatch.com (Apr 26, 2013)
Jim Cramer: 14 Stocks for the Younger Generation

at CNBC.com (Apr 25, 2013)
Movers & Shakers: Thursday’s movers: Tesla pops on Musk tweet

at MarketWatch.com (Apr 25, 2013)
Biogen Idec Total Revenues Increased 10% to $1.4 Billion in First Quarter 2013

Business Wire (Apr 25, 2013)
Cramer: Sellers Clobbering Stocks Recklessly?

at CNBC.com (Apr 24, 2013)

BIIB vs. ETF Alternatives

Company Description

Biogen Idec is a global biotechnology company that creates new standards of care in therapeutic areas with high unmet medical needs. Our business strategy is focused on discovering and developing first-in-class or best-in-class products that we can deliver to specialty markets globally.... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, June 12, 9:59 AM Biogen (BIIB -2.7%) slides after Citi analyst Yaron Werber raises concerns about regulatory data protection (previous) for Tecfidera in Europe. Weber also believes prescriptions (previous) may be overstated by 31%. The shares are downgraded from Buy to Hold. See SA contributor Brian Wilson's recent piece for a discussion of the Tecfidera prescription debate (Also: Cowen warns on possible Tecfidera double-counting) Comment! [Healthcare, On the Move]
Thursday, May 30, 9:34 AM Biogen (BIIB -1.2%) expects to delay the EU launch of its Tecfidera multiple sclerosis drug until H2, as the company wants to make the treatment's data protection clearer so that it can potentially receive longer patent protection. Biogen has already launched Tecfidera in the U.S.; the medicine is expected to receive EU clearance this quarter. 1 Comment [Healthcare]
Tuesday, May 21, 1:50 PM Biogen (BIIB +3.6%) submits Biologics License Application to the FDA for the approval of its injectable drug candidate Plegridy for the treatment of multiple sclerosis. The company says the application is supported by data from year one of a two year Phase 3 study which "met all primary and secondary endpoints." In March, BIIB said the drug cut annual relapse rates by 36% and analysts say it could generate revenue of $318M by 2017. (PR) Comment! [Healthcare, On the Move]
Monday, May 13, 4:11 PM Biogen-Idec (BIIB +4.5%) finishes the day solidly higher after announcing that the FDA has accepted its Biologics License Application for the marketing approval of Elocate, a treatment for hemophilia A. With the acceptance BIIB now has product candidates under review for both hemophilia A and B. Comment! [Healthcare, On the Move]
Monday, April 29, 10:28 AM Biogen Idec (BIIB +4.9%) gains this morning after giving an update on Tecfidera prescription performance. According to data, the drug has already garnered nearly 8% of the multiple sclerosis market through the week ended April 19, with prescriptions up 120% over the prior week. By comparison, Novartis' (NVS) Gilenya saw a market share drop to 6%. RBC sees performance on track to meet quarterly sales expectations. Comment! [Healthcare, On the Move]
Thursday, April 25, 7:47 AM More on Biogen's (BIIB) Q1: Revenue gains driven by 13% Y/Y growth of AVONEX. RITUXAN revenues reduced by $42M for damages awarded to Genentech. FAMPRYA and FUMADERM sales up 25%. Corporate partner revenues were $22M versus $3M in the comparable period last year. FY2013 guidance: revenue growth of between 16-18% and non-GAAP EPS of between $7.80-7.90. Analysts expect EPS of $7.79. Shares +2.8% premarket. (PR) Comment! [Healthcare, Earnings, On the Move]
Thursday, April 25, 6:31 AM Biogen Idec (BIIB): Q1 EPS of $1.97 beats by $0.36. Revenue of $1.4B (+10% Y/Y) misses by $0.01B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, April 25, 12:05 AM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Wednesday, April 24, 5:30 PM Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH Comment! [Earnings]
Tuesday, April 23, 7:51 AM Isis Pharmaceuticals (ISIS) initiates a Phase 2 study of ISIS-SMNRx in infants with spinal muscular atrophy. The company will get $3.5M from Biogen (BIIB) upon dosing the first infant next month. Comment! [Healthcare]
Monday, April 22, 12:12 PM Biogen (BIIB +5.8%) rises after ICI analyst Mark Schoenebaum says the company's Tecfidera multiple sclerosis drug seems to be "crushing" its competitors. Following just a week on the market, Tecfidera's sales have achieved the same level that Novartis' (NVS) Gilenya reached after three months. However, Schoenebaum warns that it's still too early to make any definitive conclusions about Tecfidera. Comment! [Healthcare, On the Move]
Wednesday, April 17, 5:15 PM S&P takes Biogen (BIIB) further into investment grade territory, raising the firm's corporate credit rating to A- with a stable outlook. Three approved multiple sclerosis treatments and "no significant patent expirations in the intermediate term" equate to "minimal" financial risk. Comment! [Healthcare]
Tuesday, April 16, 2:05 PM Biogen Idec (BIIB +1.2%) and Roche's (RHHBY.PK) Genetech lose their appeal made in a patent infringement case against GlaxoSmithKline (GSK -0.1%). The Court upheld the interpretation of a BIIB patent covering the cancer drug Arzerra, ruling that GSK didn't infringe upon the patent. Comment! [Healthcare]
Friday, April 12, 10:59 AM Elan's (ELN -1.3%) shareholders have overwhelmingly approved a plan to buy back $1B in stock following the sale of Tsabri to Biogen Idec (BIIB +2.4%), as speculation mounts that an earlier takeover indication by Royalty Pharma might be sweetened. Royalty approached ELN in February with an $11 per share potential offer, valuing the company at $6.55B, which was rejected by ELN. Last week, Ireland's Takeover Panel told the pharmaceutical investor to either step up and announce an official takeover offer for the company by May 10, or walk away. Comment! [Healthcare, Global & FX, M&A]
Friday, April 12, 10:33 AM Biogen Idec (BIIB +4%) moves higher after BofA/ Merrill Lynch upgrades the shares to Buy from Neutral. Price target raised to $246 from $187. Comment! [On the Move, Healthcare]
Tuesday, April 2, 6:08 PM Biogen Idec (BIIB) completes its purchase of Elan's (ELN) interest in Tysabri, gaining full strategic, commercial and decision-making rights to the relapsing MS drug treatment. [BIIB plans to give further details and updated financial guidance during it's upcoming Q1 earnings announcement. Shares +0.3% AH. Comment! [Healthcare, M&A]

Kenneth Hackel
Last week CT Capital sold $BIIB after tripling and bought #QCOR at $30.96, up 30% in a week.
May 14, 2:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Fuinhaz Setups for April 25 2013 | $AKAM $ALNX $BIIB $CROX $INFN $LSI $PERI $YNDX | SharePlanner http://bit.ly/12Kc6ip
Apr 25, 8:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
B/E Aerospace ($BEAV), Rock-Tenn ($RKT), Core Laboratories N.V. ($CLB), Biogen Idec ($BIIB), & Skechers ($SKX) rose Monday on unusual volume
Apr 22, 11:00 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: I like $BIIB.
Apr 22, 11:04 PM
• !Report Abuse
Add a reply...

140 characters

Jim Van Meerten
$BIIB - 96% Barchart technical buy signals - 11 new highs and up 15.13% in the last month - Relative Strength Index 78.77%
Apr 4, 4:58 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Biogen Idec ($BIIB) is surging higher. Still more bight days ahead for the biotech giant. http://yhoo.it/XWT1oi;c=
Apr 3, 3:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
DaVita HealthCare Partners ($DVA), Hertz Global ($HTZ), PAREXEL ($PRXL), Biogen Idec ($BIIB), & Conn's ($CONN) rose Tuesday on unusual vol.
Apr 3, 2:51 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: Only $DVA and $BIIB look good longterm buys.
Apr 3, 2:57 AM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Biogen Idec ($BIIB), Chicago Bridge ($CBI), American Railcar ($ARII), Kansas City ($KSU), & Flowserve ($FLS) rose Thursday on unusual vol.
Mar 29, 12:08 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
Biogen Idec ($BIIB), Nationstar ($NSM), Unifirst ($UNF), SPS Commerce ($SPSC), & Ocwen Financial ($OCN) rose Wednesday on unusual volume.
Mar 27, 11:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
$BIIB - 96% Barchart technical buy signal - 11 new highs and up 8.90% in the last month - Relative Strength Index 70.31%
Mar 21, 5:12 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3
Mar 14, 11:51 AM
Reply (2)

• !Report Abuse
View all 2 replies
Optionstrader7: no its not, going to 200. LONG!
Mar 14, 12:53 PM
• !Report Abuse
thepharmd: Guess again...BG-12 approved!
Mar 27, 4:43 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Michael Bryant
B/E Aerospace ($BEAV), Rock-Tenn ($RKT), Core Laboratories N.V. ($CLB), Biogen Idec ($BIIB), & Skechers ($SKX) rose Monday on unusual volume
Apr 22, 11:00 PM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: I like $BIIB.
Apr 22, 11:04 PM
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
DaVita HealthCare Partners ($DVA), Hertz Global ($HTZ), PAREXEL ($PRXL), Biogen Idec ($BIIB), & Conn's ($CONN) rose Tuesday on unusual vol.
Apr 3, 2:51 AM
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: Only $DVA and $BIIB look good longterm buys.
Apr 3, 2:57 AM
• !Report Abuse
Add a reply...

140 characters

Tony Kau
$BIIB exhausted - good credit spread play: Apr 190/195 calls for $0.80; expected return: 11%! http://ow.ly/i/1GyN8 http://ow.ly/iVHJ3
Mar 14, 11:51 AM
Reply (2)

• !Report Abuse
View all 2 replies
Optionstrader7: no its not, going to 200. LONG!
Mar 14, 12:53 PM
• !Report Abuse
thepharmd: Guess again...BG-12 approved!
Mar 27, 4:43 PM
• !Report Abuse
Add a reply...

140 characters

Jason F
If You Are Bullish, here are a few long stock ideas. http://bit.ly/T84cxe $SPY $SPX $DIA $LNKD $NSR $BIIB $REGN
12/21/12
Reply (3)

• !Report Abuse
View all 3 replies
FortSumter: an appointment in the Obama administration. Renewal, that is. Thanks for the list.
12/22/12
• !Report Abuse
Jason F: np
12/22/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
10 Stocks That Only Go Up http://bit.ly/Q0LtQt TJX V ABT ALXN AMT BIIB CCI CL SPG WFM
9/5/12
Reply (3)

• !Report Abuse
View all 3 replies
Ryan Mallory: not sure I understand your question.
9/6/12
• !Report Abuse
Gloube: 2 tower companies (AMT and CCI) among the 10 companies listed, interesting
10/12/12
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Sell Spectrum! http://seekingalpha.com/a/hmw5 $SPPI $OMPI $ALTH $BMY $BIIB $UHS $WCG $CYH $TARO $PDLI $EXEL #biotech #pharma #drugs #stocks
8/23/12
Reply (5)

• !Report Abuse
View all 5 replies
phemale60: not that sophisticated - just trade. I do alright tho for a newbie. I'll learn on my next vaca - sit and read. Then I'll know! ;-/
8/23/12
• !Report Abuse
Joe Springer: : )
8/23/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
14 Stocks That Only Go Up http://bit.ly/QWidJf $AKRX ALXN AMT BIIB CHD CRI DTE MO PCYC SCL TJX V WEC WFM
7/2/12
Reply (4)

• !Report Abuse
View all 4 replies
Iron Hamster: Any idea why SCL is dropping? Everything I'm reading says it's a buy and it's too early for profit taking, yet it's down on an up day.
7/26/12
• !Report Abuse
Ryan Mallory: SCL breaking some heavy support, good chance that sell-off is earnings related.
7/27/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
Perrigo (PRGO), Biogen Idec (BIIB), Mastercard (MA), Intuitive Surgical (ISRG), & Cabot Oil & Gas (COG) were the best performers in 2011.
12/23/11
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: Buying some or all of them for 2012 might not be a bad idea. http://yhoo.it/uRBq68
12/23/11
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
15 Stocks That Only Go Up http://bit.ly/w2bMai ADS ALXN AWK BIIB CHD CLH GCO MNST HURN IACI MA OKE PNM PSMT VFC
11/10/11
Reply (1)

• !Report Abuse
View all 1 replies
golfitobob: " only go up " right ! Market goes down they go with it.
11/10/11
• !Report Abuse
Add a reply...

140 characters

Justin M. Hall
8/6/11 12A ET: (VRUS, ALXN, BIIB, ILMN, PRGO) BIOTECH CORRECTION Called in June 2011 => Were You Paying Attention? http://seekingalpha.com/p/4bsg
8/6/11
Reply (1)

• !Report Abuse
View all 1 replies
John Rayhall: ILMN is down 36% pre-market seems a little overdone no?
10/7/11
• !Report Abuse
Add a reply...

140 characters

Joshua Hayes
new instablog: Rally Attempt Begins with Two Days of Gains. Medical stocks are our leaders. VRUS ELN JAZZ STAA ALXN BIIB RGEN MAKO OSUR BMY
10/5/11
Reply (1)

• !Report Abuse
View all 1 replies
cowpieTX: i manage a diagnostic imaging center for a 17b market cap company. the cuts are real and they are deep. tread carefully.
10/5/11
• !Report Abuse
Add a reply...

140 characters

BIIB Biogen Idec Inc.

BIIB

Biogen Idec Inc.